bioRASI, LLC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

Reference: Metronidazole Gel 1% · Infectious Disease / Dermatology
Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and protozoal DNA by generating reactive free radicals, leading to cell death.
Test: Metronidazole Gel 1% · Dermatology
Metronidazole gel 1% works by killing bacteria and other microorganisms that cause infections.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

bioRASI, LLC portfolio CI brief
bioRASI, LLC pipeline updates RSS

Frequently asked questions about bioRASI, LLC

What is bioRASI, LLC's pipeline?

bioRASI, LLC has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%.

Sector hub: All tracked pharma companies